Evidence map›Paper›PMID 39488208›Full record

ArticleCell chemical biology2024

A LANA peptide inhibits tumor growth by inducing CHD4 protein cleavage and triggers cell death.

Hiroki Miura, Kang-Hsin Wang, Tomoki Inagaki, Frank Chuang, Michiko Shimoda, Chie Izumiya, Tadashi Watanabe, Ryan R Davis, Clifford G Tepper, Somayeh Komaki and 3 more

Abstract read
In one paragraph

Article in Cell chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Macrophages in oncoviral infections: from immune regulators to therapeutic targets.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hiroki MiuraDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Kang-Hsin WangDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Tomoki InagakiDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Frank ChuangDepartment of Biochemistry and Molecular Medicine, School of Medicine, UC Davis, Sacramento, CA 95817, USA.
Michiko ShimodaDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Chie IzumiyaDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Tadashi WatanabeDepartment of Virology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan.
Ryan R DavisDepartment of Pathology and Laboratory Medicine, School of Medicine, UC Davis, Sacramento, CA 95817, USA.
Clifford G TepperDepartment of Biochemistry and Molecular Medicine, School of Medicine, UC Davis, Sacramento, CA 95817, USA.
Somayeh KomakiDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Ken-Ichi NakajimaDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA.
Ashish KumarDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA. Electronic address: saskumar@ucdavis.edu.
Yoshihiro IzumiyaDepartment of Dermatology, School of Medicine, University of California Davis (UC Davis), Sacramento, CA 95817, USA; Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis, Sacramento, CA 95817, USA. Electronic address: yizumiya@ucdavis.edu.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2M
Studies on Epigenetically Active Latent Chromatin MaintenanceR01AI167663 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yoshihiro Izumiya · 2022 to 2026
$2.6M
A “STICK” theranostic nanoplatform for image-guided drug delivery to brain malignanciesR01EB033677 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2022 to 2025
$2.4M
Spatiotemporal Gene Regulation and KSHV ReplicationR01CA225266 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2018 to 2022
$1.8M
Development of Precision Analyses to Reveal "Hit&Run" EffectsR21AI155515 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO · 2021 to 2022
$432k
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225266NCI NIH HHS R01 CA232845NIAID NIH HHS R01 AI167663NIAID NIH HHS R21 AI155515NIBIB NIH HHS R01 EB033677
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) establishes a latent infection, and viral genes are poised to be transcribed in the latent chromatin. In the poised chromatins, KSHV latency-associated nuclear antigen (LANA) interacts with cellular chromodomain-helicase-DNA-binding protein 4 (CHD4) and inhibits viral promoter activation. CHD4 is known to regulate cell differentiation by preventing enhancers from activating promoters. Here, we identified a putative CHD4 inhibitor peptide (VGN73) from the LANA sequence corresponding to the LANA-CHD4 interaction surface. The VGN73 interacts with CHD4 at its PHD domain with a dissociation constant (K

Indexed as

Mi-2 Nucleosome Remodeling and Deacetylase ComplexAnimalsAntigens, ViralAntineoplastic AgentsCell DeathCell DifferentiationCell ProliferationHerpesvirus 8, HumanHumansMiceMice, NudeNuclear ProteinsPeptidesAntigens, ViralAntineoplastic AgentsCHD4 protein, humanlatency-associated nuclear antigenMi-2 Nucleosome Remodeling and Deacetylase ComplexNuclear ProteinsPeptidesapoptosisautophagycancercell differentiationCHD4KSHVLANAleukemiamonocytepeptide

Identifiers

PMID39488208
PMCPMC11588034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.